Christopher Fröhlich

Christopher Fröhlich

Auto-generated profile, based on publicly available information

Christopher Fröhlich

UiT The Arctic University of Norway

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in mSphere
Verified
Journal Article
Open access
PDF file
CFChristopher Fröhlich
Christopher Fröhlich
VSVidar Sørum
Vidar Sørum
ATAne Molden Thomassen
Ane Molden Thomassen
PJPål Jarle Johnsen
Pål Jarle Johnsen
HLHanna-Kirsti S. Leiros
Hanna-Kirsti S. Leiros
ØSØrjan Samuelsen
Ørjan Samuelsen
The recent introduction of novel β-lactam/β-lactamase inhibitor combinations like ceftazidime-avibactam has increased our ability to treat infections caused by multidrug-resistant Gram-negative bacteria, including carbapenemase-producing Enterobacterales . However, the increasing number of cases of reported resistance to ceftazidime-avibactam is a concern. OXA-48 is a carbapenemase that has no significant effect on ceftazidime, but is inhibited by avibactam. Since isolates with OXA-48 frequently harbor extended-spectrum β-lactamases that are inhibited by avibactam, it is likely that ceftazidime-avibactam will be used to treat infections caused by OXA-48-producing Enterobacterales. Our data show that exposure to ceftazidime-avibactam can lead to changes in OXA-48, resulting in increased ability to hydrolyze ceftazidime and withstand the inhibitory effect of avibactam. Thus, resistance toward ceftazidime-avibactam among OXA-48-producing Enterobacterales should be monitored. Interestingly, the compromising effect of the amino acid substitutions in OXA-48 on other β-lactams and the effect of ceftazidime-avibactam exposure on the epidemic OXA-48 plasmid indicate that the evolution of ceftazidime-avibactam resistance comes with collateral effects.

23 February 2024 in Nature Catalysis
Verified
Journal Article
Open access
PDF file
CFChristopher Fröhlich
Christopher Fröhlich
HBH. Adrian Bunzel
H. Adrian Bunzel
KBKarol Buda
Karol Buda
AMAdrian J. Mulholland
Adrian J. Mulholland
MKMarc Van Der Kamp
Marc Van Der Kamp
NTNobuhiko Tokuriki
Nobuhiko Tokuriki
Epistasis, the non-additive effect of mutations, can provide combinatorial improvements to enzyme activity that substantially exceed the gains from individual mutations. Yet the molecular mechanisms of epistasis remain elusive, undermining our ability to predict pathogen evolution and engineer biocatalysts. Here we reveal how directed evolution of a β-lactamase yielded highly epistatic activity enhancements. Evolution selected four mutations that increase antibiotic resistance 40-fold, despite their marginal individual effects (≤2-fold). Synergistic improvements coincided with the introduction of super-stochiometric burst kinetics, indicating that epistasis is rooted in the enzyme’s conformational dynamics. Our analysis reveals that epistasis stemmed from distinct effects of each mutation on the catalytic cycle. The initial mutation increased protein flexibility and accelerated substrate binding, which is rate-limiting in the wild-type enzyme. Subsequent mutations predominantly boosted the chemical steps by fine-tuning substrate interactions. Our work identifies an overlooked cause for epistasis: changing the rate-limiting step can result in substantial synergy that boosts enzyme activity.

11 July 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CFChristopher Fröhlich
Christopher Fröhlich
VSVidar Sørum
Vidar Sørum
NTNobuhiko Tokuriki
Nobuhiko Tokuriki
PJPål Jarle Johnsen
Pål Jarle Johnsen
ØSØrjan Samuelsen
Ørjan Samuelsen
Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime. Consequently, cefiderocol represents a treatment alternative for infections caused by MDR Gram-negatives. To study the role of cefiderocol on resistance development and on the evolution of β-lactamases from all Ambler classes, including KPC-2, CTX-M-15, NDM-1, CMY-2 and OXA-48. Directed evolution, using error-prone PCR followed by selective plating, was utilized to investigate how the production and the evolution of different β-lactamases cause changes in cefiderocol susceptibility determined using microbroth dilution assays (MIC and IC50). We found that the expression of blaOXA-48 did not affect cefiderocol susceptibility. On the contrary, the expression of blaKPC-2, blaCMY-2, blaCTX-M-15 and blaNDM-1 substantially reduced cefiderocol susceptibility by 4-, 16-, 8- and 32-fold, respectively. Further, directed evolution on these enzymes showed that, with the acquisition of only 1–2 non-synonymous mutations, all β-lactamases were evolvable to further cefiderocol resistance by 2- (NDM-1, CTX-M-15), 4- (CMY-2), 8- (OXA-48) and 16-fold (KPC-2). Cefiderocol resistance development was often associated with collateral susceptibility changes including increased resistance to ceftazidime and ceftazidime/avibactam as well as functional trade-offs against different β-lactam drugs. The expression of contemporary β-lactamase genes can potentially contribute to cefiderocol resistance development and the acquisition of mutations in these genes results in enzymes adapting to increasing cefiderocol concentrations. Resistance development caused clinically important cross-resistance, especially against ceftazidime and ceftazidime/avibactam.

19 July 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
CSChristian Schnaars
Christian Schnaars
GKGeir Kildahl-Andersen
Geir Kildahl-Andersen
APAnthony Prandina
Anthony Prandina
RPRoya Popal
Roya Popal
SRSylvie Large Radix
Sylvie Large Radix
OÅOve Alexander Høgmoen Åstrand
Ove Alexander Høgmoen Åstrand

21 May 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ØSØrjan Samuelsen
Ørjan Samuelsen
AÅAlexander Åstrand
Alexander Åstrand
CFChristopher Fröhlich
Christopher Fröhlich
AHAdam Heikal
Adam Heikal
SSSusann Skagseth
Susann Skagseth
PRPål Rongved
Pål Rongved
Carbapenem-resistant Gram-negative pathogens are a critical public health threat and there is an urgent need for new treatments. Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo β-lactamase (MBL) families. The recent introduction of SBL carbapenemase-inhibitors has provided alternative therapeutic options. Unfortunately, there are no approved inhibitors of MBL-mediated carbapenem-resistance and treatment options for infections caused by MBL-producing Gram-negatives are limited. Here, we present ZN148, a zinc-chelating MBL-inhibitor capable of restoring the bactericidal effect of meropenem and in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains (n=234). Moreover, ZN148 was able to potentiate the effect of meropenem against NDM-1-producing Klebsiella pneumoniae in a murine neutropenic peritonitis model. ZN148 showed no inhibition of the human zinc-containing enzyme glyoxylase II at 500 μM and no acute toxicity was observed in an in vivo mouse model with cumulative dosages up to 128 mg/kg. Biochemical analysis showed a time-dependent inhibition of MBLs by ZN148 and removal of zinc ions from the active site. Addition of exogenous zinc after ZN148 exposure only restored MBL activity by ∼30%, suggesting an irreversible mechanism of inhibition. Mass-spectrometry and molecular modelling indicated potential oxidation of the active site Cys221 residue. Overall, these results demonstrate the therapeutic potential of a ZN148-carbapenem combination against MBL-producing Gram-negative pathogens and that ZN148 is a highly promising MBL inhibitor, capable of operating in a functional space not presently filled by any clinically approved compound.

28 April 2021 in mSphere
Verified
Journal Article
Open access
CFChristopher Fröhlich
Christopher Fröhlich
MBMorten Boland
Morten Boland
KHKlaus Harms
Klaus Harms
VHViivi H. A. Hirvonen
Viivi H. A. Hirvonen
BLBjarte Lund
Bjarte Lund
HLHanna-Kirsti S. Leiros
Hanna-Kirsti S. Leiros
Very low antibiotic concentrations have been shown to drive the evolution of antimicrobial resistance. While substantial progress has been made to understand the driving role of low concentrations during resistance development for different antimicrobial classes, the importance of β-lactams, the most commonly used antibiotics, is still poorly studied.